Xeris Biopharma Holdings Inc（XERS）の財務XERSXeris Biopharma Holdings Inc

Xeris Biopharma Holdings, Inc. (XERS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue -Recorlev, accounting for 61.6% of total sales, equivalent to $56.78M. Other significant revenue streams include Product revenue - Gvoke and Product revenue - Keveyis. Understanding this composition is critical for investors evaluating how XERS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Xeris Biopharma Holdings, Inc. maintains a gross margin of 83.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 5.62%, while the net margin is -33.77%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively XERS converts its operational activities into shareholder value.

In the context of the broader market, XERS competes directly with industry leaders such as RXRX and NVAX. With a market capitalization of $2.00B, it holds a significant position in the sector. When comparing efficiency, XERS's gross margin of 83.47% stands against RXRX's -49.82% and NVAX's 78.27%. Such benchmarking helps identify whether Xeris Biopharma Holdings, Inc. is trading at a premium or discount relative to its financial performance.

Xeris Biopharma has demonstrated strong revenue growth, with Q2 2026 revenue at $92.1 million and a gross margin of 83.47%. The company has also raised its full-year revenue guidance to between $385 million and $390 million, indicating confidence in continued growth.